All In Biotech

Drug Trial Radar · NCT03370913

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions

Last checked: Nov 20, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

144

Actual

Start

Dec 19, 2017

Primary completion

Nov 16, 2020

Study completion Nov 20, 2024

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Dec 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase III clinical study will assess the impact of BMN 270 (compared to FVIII prophylaxis) on the number of bleeding episodes irrespective of exogenous FVIII replacement treatment in the efficacy evaluation period (EEP) (from Week 5 post-BMN 270 infusion (Study Day 33) or the end of FVIII prophylaxis plus the washout period (3 days for products of standard half-life or plasma-derived and 5 days for products of extended half-life), whichever is later, to last visit by the data cut-off for the 2-year analysis, hereafter referred to as "Post FVIII Prophylaxis to Last Visit"). The study will also assess the impact of BMN 270 (compared to FVIII prophylaxis) on: the number of bleeding episodes requiring exogenous FVIII treatment in "Post FVIII Prophylaxis to Last Visit", FVIII activity as measured by chromogenic sustrate assay at Week 104 following intravenous infusion of BMN 270, usage of exogenous FVIII replacement therapy in "Post FVIII Prophylaxis to Last Visit", health-related quality of life patient-reported outcomes at week 104 following intravenous infusion of BMN 270. The study will also evaluate the safety of the BMN 270.

Conditions

  • Hemophilia A

Interventions

  • valoctocogene roxaparvovecBiological

    Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Annualized Number of Bleeding Episodes Irrespective of Exogenous FVIII Replacement Treatment [Annualized Bleeding Rate (ABR) for All Bleeds] in EEP.Time frame: Baseline to efficacy evaluation period (EEP)

Locations

49 sites in 13 countries. Site status is shown where the registry gives one.

  • Los Angeles Orthopedic Hospital, Orthopedic Hemophilia Treatment Center

    Los Angeles, California

  • UC Davis Hemophilia Treatment Center

    Sacramento, California

  • University of California San Diego, Hematology and Oncology, Hemophilia &Thrombosis Treatment Center

    San Diego, California

  • UCSF Medical Center

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • St. Joseph's Children's Hospital, Center for Bleeding and Clotting Disorders

    Tampa, Florida

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Hematology

    Chicago, Illinois

  • James Graham Brown Cancer Center

    Louisville, Kentucky

  • Tulane University Hematology & Medical Oncology

    New Orleans, Louisiana

  • University of Michigan, Pediatric Hematology and Oncology

    Ann Arbor, Michigan

  • Wayne State University, Detroit Medical Center

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Washington University School of Medicine, Department of Pediatrics, Division of Hematology/Oncology

    St Louis, Missouri

  • UNC Hemophilia and Thrombosis Center

    Chapel Hill, North Carolina

  • Nationwide Children's Hospital

    Columbus, Ohio

  • The Royal Adelaide Hospital (RAH)

    Adelaide, Australia

  • Royal Brisbane and Women's Hospital

    Brisbane, Australia

  • Alfred Hospital

    Melbourne, Australia

  • Fiona Stanley Hospital

    Perth, Australia

  • Royal Prince Alfred Hospital

    Sydney, Australia

  • University Hospital Leuven

    Leuven, Belgium

  • Campinas Estadual University (UNICAMP) / Campinas Hemocentro / Hematologia E Hemoterapia Center

    Campinas, Brazil

  • Parana's Hematology And Hemotherapy Center (HEMEPAR)

    Curitiba, Brazil

  • Arthur De Siqueira Cavalcanti Hematology State Institute

    Rio de Janeiro, Brazil

  • Sao Paulo University Clinical Hospital

    São Paulo, Brazil

  • Holy Spirit Hematology and Hemotherapy Center

    Vitória, Brazil

  • Regional University Hospital of Lille (CHRU de Lille)

    Lille, France

  • Hopital de la Timone Marseille - Assistance Publique des Hopitaux de Marseille

    Marseille, France

  • Vivantes Clinic im Friedrichshain- Landsberger Allee

    Berlin, Germany

  • University Clinic Bonn

    Bonn, Germany

  • Chaim Sheba Medical Center

    Ramat Gan, Israel

  • Maggiore Polyclinic Hospital, IRCCS Ca' Granda, Center for Hemophilia and Thrombosis Angelo Bianchi Bonomi

    Milan, Italy

  • Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care Center

    Johannesburg, South Africa

  • Department of Pediatrics, Kyung Hee University Hospital at Gangdong

    Seoul, South Korea

  • Hospital Teresa Herrera

    A Coruña, Spain

  • University Hospital Virgen del Rocio (HUVR)

    Seville, Spain

  • Changhua Christian Hospital

    Changhua, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.